MedTrace Logo

A Comparative Analysis of Two Hyaluronic Acid Fillers for Nasolabial Fold Correction

NCT06351293 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-01-16

No results posted yet for this study

Summary

This is a randomized, split-face, subject-blinded, comparative study. Subjects will receive initial treatment with Defyne on one of the NLFs and with RHA3 on the other based on the pre-determined randomization.

4 weeks after the initial treatment, subjects will receive optional touch-up on one side or both sides at the Investigator's discretion for optimal correction.

Subjects to return to the site at Month 3, 6, and 12 for follow-ups.

Conditions

  • Wrinkle

Interventions

DEVICE

Defyne Treatment in Nasolabial Fold

Defyne will be injected into left or right nasolabial fold, per randomization.

DEVICE

RHA3 Treatment in Nasolabial Fold

RHA3 will be injected into left or right nasolabial fold, per randomization.

Sponsors & Collaborators

  • Galderma R&D

    lead INDUSTRY

Principal Investigators

  • Steven Weiner, MD · The Aesthetic Clinique

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
22 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-02-21
Primary Completion
2025-03-17
Completion
2025-04-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06351293 on ClinicalTrials.gov